Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK

The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.

Investors Business Daily

Is This Biotech Stock's OpenAI Partnership a Game-Changer?

With AI making waves in biotech, could this biotech’s OpenAI partnership be the catalyst for new highs?

Barchart

The U.S. Is Close To Bankrolling Moderna's Bird Flu Vaccine As Third Dairy Worker Tests Positive

Moderna stock seesawed Thursday after confirming the U.S. government is nearing a deal to fund its pandemic bird flu vaccine.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Option Trade On Volatile Moderna Stock Could Return 28% By Mid-July

This iron condor trade on Moderna stock has the potential to return 28% if the stock price stays between 118.90 and 181.10.

Investors Business Daily

Novavax strikes $1.2 billion deal with Sanofi in major turnaround

It's a major turnaround for a drug company that warned last year about its ability to stay in business.

Axios

Moderna Tumbles After The FDA Throws A Curveball On Its Second Product

Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.

Investors Business Daily

Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views

Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Coroner probes vaccine link to young woman's death

A Victorian coroner is investigating whether a woman's death from heart inflammation after receiving her third COVID-19 jab was due to the Moderna vaccine.

AAP

Dow Jones Climbs As Donald Trump Stock Dives; Cathie Wood Loads Up On This Amid 42% Plunge

The Dow Jones gained on the stock market today. A Donald Trump-linked entity fell while Cathie Wood bought a diving stock.

Investors Business Daily

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

StockNews.com

Covid vaccines cut risk of virus-related heart failure and blood clots, study finds

Researchers say jabs substantially reduce for up to a year the chances of serious cardiovascular complications

The Guardian - UK

Stocks Close Mildly Lower on Caution Ahead of Tuesday’s U.S. CPI Report

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed -0.37%. Stocks Monday traded mildly lower on a +2.3 bp rise in the 10-year T-note...

Barchart

Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test

Moderna stock surged Monday, nearing its first breakout in over a year, after launching a third study of its cancer vaccine.

Investors Business Daily

Moderna Surges 14% After Covid Vaccine-Maker Surprises With Fourth-Quarter Profit

Moderna stock surged Thursday after the firm beat quarterly expectations, including turning around a surprise profit.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Moderna (MRNA) Earnings Analysis: Buy or Watch for Gains?

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash burn reflect uncertainty around its near-term prospects. As MRNA is set to release its fourth-quarter 2023 results this Thursday, let’s find…

StockNews.com

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

LiveScience

New mRNA 'cancer vaccine' trial launches in UK

The first U.K. patient has received a dose of "cancer vaccine" in a new trial.

StockNews.com

Moderna (MRNA) vs. Exelixis (EXEL) - Which Biotech Stock Is Worth Buying?

The biotech industry is poised for long-term growth, supported by the advancements in personalized medicine and integration with information technology. While leading biotech stocks Moderna (MRNA) and Exelixis (EXEL) should benefit from the industry tailwinds, let us predict which stock is worth buying.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

‘Medicine is going personalised’: Moderna’s UK boss on the coming vaccine revolution

Darius Hughes was a key figure in Pfizer’s pioneering Covid vaccine drive. Now he has changed companies – and sees a big future for mRNA technology

Investors Business Daily

60% Of This Year's Top Stocks Are In This Sector (It's Not Tech)

Just when it looked like technology stocks took over the S&P 500 — another sector is on the rise.

Inverse

A Biochemist Reveals The One Tech That Could Revolutionize Drug Discovery

How mRNA-based drugs interact with the immune system and how they are degraded in human cells can help lead to safe, durable, and effective treatments.

Top News

Florida Surgeon General's Claims on COVID Vaccines Debunked as Nonsense

Explore the debunked claims made by the Florida State Surgeon General regarding COVID vaccines and the integration of contaminants into DNA in this insight...

The Conversation

Drugs of the future will be easier and faster to make, thanks to mRNA – after researchers work out a few remaining kinks

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often…

1 … 4 5 6 7

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

538 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.